Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31410961 | 1.00 | CYP3A4 (0.59) | CYP3A4MAPTACHEKDM4EALDH1A1 | |
| SCHEMBL22689188 | 0.88 | CYP3A4 (0.46) | CYP3A4MAPTACHEKDM4EALDH1A1 | |
| SCHEMBL16134866 | 0.83 | CYP3A4 (0.62) | CYP3A4MAPTACHEKDM4EALDH1A1 | |
| SCHEMBL21426605 | 0.80 | AKR1B1 (0.39) | MAOAMAOB | |
| SCHEMBL1399862 | 0.79 | METAP1 (0.55) | CYP3A4MAPTACHEKDM4EALDH1A1 | |
| SCHEMBL21426609 | 0.78 | AKR1B1 (0.38) | MAOAMAOB | |
| SCHEMBL2928543 | 0.76 | CYP3A4 (0.53) | CYP3A4ACHEMEN1KMT2ACA1 | |
| SCHEMBL29557279 | 0.76 | CYP3A4 (0.53) | CYP3A4ACHEMEN1KMT2ACA1 | |
| SCHEMBL2334456 | 0.76 | METAP1 (0.57) | CYP3A4MAPTACHEKDM4EALDH1A1 | |
| SCHEMBL16156009 | 0.75 | CYP3A4 (0.56) | CYP3A4MAPTACHEKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074917-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | PURDUE RESEARCH FOUNDATION | 2025-03-06 | — | — | US | disclosed |
| US-20240287089-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | PURDUE RESEARCH FOUNDATION (US) | 2024-08-29 | — | — | US | disclosed |
| WO-2023215238-A1 | PREPARATION AND USES OF 7-AZAINDENOISOQUINOLINES | PURDUE RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2023215238-A1 | PREPARATION AND USES OF 7-AZAINDENOISOQUINOLINES | PURDUE RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | WO | disclosed |
| US-9073920-B2 | Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes therfor | PURDUE RESEARCH FOUNDATION (US) | 2015-07-07 | — | — | US | disclosed |
| US-9073920-B2 | Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes therfor | PURDUE RESEARCH FOUNDATION (US) | 2015-07-07 | — | — | US | disclosed |
| US-9034870-B2 | Azaindenoisoquinoline topoisomerase I inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-9034870-B2 | Azaindenoisoquinoline topoisomerase I inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2015-05-19 | — | — | US | disclosed |
| US-20140187547-A1 | AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187547-A1 | AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20080214576-A1 | Topoisomerase Inhibitors and Prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | US | disclosed |
| US-7250410-B2 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | VIA PHARMACEUTICALS, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070015751-A1 | Nitro and amino substituted heterocycles as topoisomerase I targeting agents | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2007-01-18 | — | — | US | disclosed |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | BAY CITY CAPITAL LLC | 2004-08-05 | — | — | US | disclosed |
| EP-1392663-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2004-03-03 | — | — | EP | disclosed |
| US-6509344-B1 | A method for treating a patient having cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 1, whereupon said patient is treated for cancer, and wherein the cancer is | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-01-21 | — | — | US | disclosed |
| WO-2002098865-A2 | CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF | NEURO3D (FR) | 2002-12-12 | — | — | WO | disclosed |
| EP-1123099-A4 | NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2002-08-21 | — | — | EP | disclosed |
| EP-1123099-A1 | NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000021537-A1 | NOVEL INDENOISOQUINOLINES AS ANTINEOPLASTIC AGENTS | PURDUE RESEARCH FOUNDATION (US) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015751-A1 | Nitro and amino substituted heterocycles as topoisomerase I targeting agents | TOP1, TOP2A, TOP2B | CYP3A4 529/4885MAPT 4497/4885ACHE 2045/4885 |
| US-20250074917-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | MYC, MYCBP, DNMT1 | CYP3A4 3176/4885MAPT 2450/4885ACHE 4790/4885 |
| US-20140187547-A1 | AZAINDENOISOQUINOLINE TOPOISOMERASE I INHIBITORS | TOP2A, TOP1, TOP2B | CYP3A4 558/4885MAPT 3992/4885ACHE 1609/4885 |
| US-20080214576-A1 | Topoisomerase Inhibitors and Prodrugs | TOP2A, TOP1, TOP2B | CYP3A4 1499/4885MAPT 2510/4885ACHE 2261/4885 |
| US-20040152888-A1 | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof | PDE7A, PDE3B, PDE3A | CYP3A4 264/4885MAPT 4388/4885ACHE 163/4885 |
| US-20240287089-A1 | Preparation and Uses of 7-Azaindenoisoquinolines | MYC, MYCBP, DNMT1 | CYP3A4 3176/4885MAPT 2450/4885ACHE 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.